Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SEPN
3351
Septerna Inc
SEPN
$2.11B
| $1.06M | ﹤0.01% |
38,147
+8,045
| +27% | +$192K |
|
3352
IBEX
IBEX
$482M
| $1.06M | ﹤0.01% |
27,771
+2,235
| +9% | +$82.7K |
|
3353
Bowman Consulting
BWMN
$731M
| $1.06M | ﹤0.01% |
32,087
+1,872
| +6% | +$71K |
|
|
GRDN
3354
Guardian Pharmacy Services
GRDN
$2.44B
| $1.06M | ﹤0.01% |
35,185
+7,212
| +26% | +$204K |
|
3355
Neuropace
NPCE
$498M
| $1.06M | ﹤0.01% |
68,555
+3,560
| +5% | +$47.6K |
|
3356
First Trust NASDAQ Cybersecurity ETF
CIBR
$16B
| $1.06M | ﹤0.01% |
14,792
+7,546
| +104% | +$565K |
|
3357
CALL
Array Technologies
ARRY
$796M
| $1.05M | ﹤0.01% |
114,300
-150,000
| -57% | -$1.29M |
|
|
MPT
3358
Medical Properties Trust
MPT
$2.51B
| $1.05M | ﹤0.01% |
210,354
+7,373
| +4% | +$38.4K |
|
3359
Petco
WOOF
$817M
| $1.05M | ﹤0.01% |
373,854
+230,207
| +160% | +$745K |
|
3360
Lightspeed Commerce
LSPD
$1.42B
| $1.05M | ﹤0.01% |
86,897
+73,657
| +556% | +$872K |
|
|
INGM
3361
Ingram Micro Holding
INGM
$6.53B
| $1.05M | ﹤0.01% |
49,142
+48,831
| +15,701% | +$1.06M |
|
3362
USCB Financial Holdings
USCB
$418M
| $1.05M | ﹤0.01% |
56,822
+5,577
| +11% | +$99.7K |
|
3363
Pulmonx
LUNG
$92.8M
| $1.04M | ﹤0.01% |
472,251
+132,569
| +39% | +$249K |
|
3364
PUT
AT&T
T
$168B
| $1.04M | ﹤0.01% |
42,000
| – | – |
|
3365
Citizens
CIA
$198M
| $1.04M | ﹤0.01% |
215,908
+13,689
| +7% | +$75.4K |
|
3366
Excelerate Energy
EE
$1.12B
| $1.04M | ﹤0.01% |
37,171
+3,389
| +10% | +$91.7K |
|
|
CLDT
3367
Chatham Lodging
CLDT
$601M
| $1.04M | ﹤0.01% |
153,011
-136,041
| -47% | -$903K |
|
|
SOMN
3368
The Southern Company 2025 Series A Corp Units
SOMN
| $1.04M | ﹤0.01% |
+20,687
| New | +$1.03M |
|
3369
Graham Corp
GHM
$1.3B
| $1.04M | ﹤0.01% |
16,212
+350
| +2% | +$21.1K |
|
3370
Hycroft Mining Holding Corp
HYMC
$2.48B
| $1.04M | ﹤0.01% |
43,638
+38,221
| +706% | +$423K |
|
3371
Real Brokerage
REAX
$523M
| $1.04M | ﹤0.01% |
284,065
+81,730
| +40% | +$316K |
|
3372
Tootsie Roll Industries
TR
$3.02B
| $1.04M | ﹤0.01% |
29,122
-9,454
| -25% | -$358K |
|
3373
Forum Energy Technologies
FET
$927M
| $1.04M | ﹤0.01% |
28,023
-142
| -0.5% | -$4.41K |
|
3374
Cable One
CABO
$206M
| $1.03M | ﹤0.01% |
9,112
+921
| +11% | +$126K |
|
3375
MetroCity Bankshares
MCBS
$1.05B
| $1.03M | ﹤0.01% |
38,710
+6,194
| +19% | +$165K |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.